KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability (2019 - 2025)

Historic Non-Current Deferred Tax Liability for Supernus Pharmaceuticals (SUPN) over the last 8 years, with Q1 2025 value amounting to $981000.0.

  • Supernus Pharmaceuticals' Non-Current Deferred Tax Liability fell 9496.95% to $981000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $981000.0, marking a year-over-year decrease of 9496.95%. This contributed to the annual value of $5.0 million for FY2024, which is 9682.53% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non-Current Deferred Tax Liability of $981000.0 as of Q1 2025, which was down 9496.95% from $5.0 million recorded in Q4 2024.
  • In the past 5 years, Supernus Pharmaceuticals' Non-Current Deferred Tax Liability registered a high of $229.6 million during Q4 2021, and its lowest value of $981000.0 during Q1 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Non-Current Deferred Tax Liability value was $35.2 million (recorded in 2023), while the average stood at $60.2 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first soared by 9798.06% in 2022, then plummeted by 9682.53% in 2024.
  • Supernus Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $229.6 million in 2021, then decreased by 19.58% to $184.7 million in 2022, then decreased by 15.39% to $156.3 million in 2023, then crashed by 96.83% to $5.0 million in 2024, then tumbled by 80.23% to $981000.0 in 2025.
  • Its last three reported values are $981000.0 in Q1 2025, $5.0 million for Q4 2024, and $7.4 million during Q3 2024.